Tarsus Pharmaceuticals, Inc. TARS PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s PP&E (net)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported PP&E (net) of $17.67M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s PP&E (net) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s PP&E (net) increased by 534.1% year-over-year, from $2.79M to $17.67M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s PP&E (net)?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s PP&E (net) has grown at a 84.3% compound annual growth rate (CAGR), from $548K to $11.67M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.